Literature DB >> 1503757

Recombinant peptides as immunogens: a comparison of protocols for antisera production using the pGEX system.

H F Oettinger1, R Pasqualini, M Bernfield.   

Abstract

Using an inducible vector system that directs high-level production and rapid purification of recombinant protein, we have immunized mice with peptides prepared by several methods: 1) samples fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) subsequently transferred to PVDF membrane and subcutaneously implanted in mice; 2) samples cut directly from SDS-PAGE gels and injected intraperitoneally; 3) injection of recombinant protein bound to agarose beads; and 4) injection of log-phase E. coli transformed with recombinant vector. All four strategies yielded specific antisera reacting with both the parental fusion protein and the recombinant fragment as determined by enzyme-linked immunosorbent assay and immunoblot analysis. Specific recognition of the recombinant fragment was demonstrated by a competitive inhibition assay in which the parental fusion protein abrogated reactivity of serum with the isolated recombinant fragment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503757

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  3 in total

1.  XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation.

Authors:  N Kuzhandaivelu; Y S Cong; C Inouye; W M Yang; E Seto
Journal:  Nucleic Acids Res       Date:  1996-12-01       Impact factor: 16.971

2.  A human endogenous retrovirus suppresses translation of an associated fusion transcript, PLA2L.

Authors:  P E Kowalski; D L Mager
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

3.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.

Authors:  R B Roden; E M Weissinger; D W Henderson; F Booy; R Kirnbauer; J F Mushinski; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.